Exchange: NASDAQ·Updated 07:30 PM EDT
MDGL logo

MDGLMadrigal Pharmaceuticals Inc

$536.70
$23.31
(4.16%)
Today
Closed $536.70
$0.00
(0.00%)
After Hours
EarningsAug 5
Mkt Cap$12.37B
Vol294,015.00
News
all
press releases
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH PR Newswire SUZHOU, China and MLNDAL, Sweden, July 1, 2026 SUZHOU, China and MLNDAL, Sweden, July 1, 2026 /PRNewswire...
PR Newswire
News Placeholder
More News
News Placeholder
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.
Zacks
News Placeholder
Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
Zacks
News Placeholder
Madrigal Pharmaceuticals Q1 Earnings Call Highlights
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported first-quarter 2026 net sales of $311.3 million as executives said demand for its MASH therapy Rezdiffra continued to build in a market they described as still early in development. On the company's earnings call, management highlighted patient growth...
MarketBeat
News Placeholder
Madrigal Pharmaceuticals (NASDAQ:MDGL) Receives Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $620.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Wednesday...
MarketBeat
News Placeholder
Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates
Madrigal (MDGL) delivered earnings and revenue surprises of +9.97% and +3.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Madrigal Pharmaceuticals Posts Wider Loss In Q1
(RTTNews) - Wednesday, Madrigal Pharmaceuticals, Inc. (MDGL) announced its first-quarter financial results, reporting a net loss of $94.4 million, or $3.25 a share, compared to $73.2 million, or $2.61 a share, in the previous year...
Nasdaq News: Markets
News Placeholder
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowheads clinical stage RNA...
Business Wire
News Placeholder
Vanguard Group Inc. Trims Stake in Madrigal Pharmaceuticals, Inc. $MDGL
Vanguard Group Inc. reduced its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 0.2% in the fourth quarter, according to its most recent 13F filing with the...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.